Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Controlled Pilot Study to Assess Soft Tissue Reaction at the Crestal Part of a Dental Implant With ESTA Surface

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02159183
Recruitment Status : Terminated (5-Y FUP will not result in new perception, no diff. between groups at 1+3y FUP)
First Posted : June 9, 2014
Results First Posted : March 7, 2019
Last Update Posted : April 2, 2019
Sponsor:
Information provided by (Responsible Party):
Institut Straumann AG

Brief Summary:
This study will investigate the effect on the soft tissue that is in contact with a dental implant with a modified surface of the neck (the part of the implant that is above the bone and in contact with the soft gum tissue).

Condition or disease Intervention/treatment Phase
Teeth Loss Device: Standard Plus ESTA STL Roxolid implant Device: Standard Plus STL implant Not Applicable

Detailed Description:

This is a prospective, controlled, randomised clinical pilot study with parallel groups and blinded subject.

The design has been chosen to obtain data to base a sample size calculation for future studies on by comparing the degree of mucosal inflammation of the mucosa in conjunction with the modified surface of the top of the test implant and the machined surface on the top of the control implant.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 43 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: A Controlled Clinical Pilot Study to Assess Soft Tissue Reaction at the Crestal Part of a Dental Implant With ESTA Surface
Study Start Date : January 2012
Actual Primary Completion Date : September 2013
Actual Study Completion Date : September 27, 2016

Arm Intervention/treatment
Experimental: Standard Plus ESTA STL Roxolid implant
This arm will receive the Straumann Soft Tissue Level Standard Plus Implant Ø 4.1 mm Regular Neck, SLActive® Roxolid, with a modified surface of the neck (ESTA).
Device: Standard Plus ESTA STL Roxolid implant
The patient will receive a Straumann Soft Tissue Level Standard Plus Implant Ø 4.1 mm Regular Neck, SLActive® Roxolid, with a modified surface of the neck (ESTA). At 8-12 weeks after insertion, the implant will be loaded.

Active Comparator: Standard Plus STL implant
This arm will receive the Straumann Soft Tissue Level Standard Plus Implant Ø4.1mm Regular Neck,SLActive® Titanium grade IV, with a machined surface of the neck.
Device: Standard Plus STL implant
The patient will receive a Straumann Soft Tissue Level Standard Plus Implant Ø4.1mm Regular Neck,SLActive® Titanium grade IV, with a machined surface of the neck. At 8-12 weeks after insertion, the implant will be loaded.




Primary Outcome Measures :
  1. Sulcus Bleeding Index (According to Mombelli et al 1987) [ Time Frame: 12 months ]

    The primary endpoint is the difference of Sulcus Bleeding Index (according to Mombelli et al 1987) between baseline (final loading) and 12 months.

    The inflammatory status of the mucosa will be evaluated by means of a UNC 15 periodontal probe.

    0: No bleeding when a periodontal probe is passed along the peri-implant sulcus

    1. Isolated bleeding spots are recognizable
    2. Confluent bleeding line along the marginal mucosa
    3. Profound bleeding.


Secondary Outcome Measures :
  1. Sulcus Bleeding Index (According to Mombelli et al 1987) [ Time Frame: 3 years ]

    The inflammatory status of the mucosa will be evaluated by means of a UNC 15 periodontal probe.

    0: No bleeding when a periodontal probe is passed along the peri-implant sulcus

    1. Isolated bleeding spots are recognizable
    2. Confluent bleeding line along the marginal mucosa
    3. Profound bleeding.

  2. Soft Tissue Healing Evaluation [ Time Frame: 10 days and 12 weeks ]
    Assessment of the wound healing by classifying the implantation site (normal or compromised healing).

  3. Oral Hygiene [ Time Frame: Screening, 6, 12, 36 months ]
    Full mouth plaque index (FMPI) and full mouth bleeding on probing index (FMBoP) will be recorded as an indicator for the Oral Hygiene. The indexes are given in percent [%] calculated as the total numbers of surfaces with plaque or bleeding divided by the total number of teeth surfaces x100.

  4. Recession of Gingival Margin Buccally and Lingually/Palatal [ Time Frame: 1 and 3 years ]
    The recession of the gingival margin will be measured (distance from the gingival margin to the crown/implant margin) by using an UNC 15 periodontal probe. Changes in (averaged) recession at the follow-up visits 12+36 months compared to baseline visit ( final loading ) are displayed

  5. Probing Pocket Depth (PPD) [ Time Frame: 6 months, 1 and 3 years ]

    The PPD will be measured from the mucosal margin to the bottom of the periimplant pocket by means of an UNC 15 probe.

    Probing pocket depth (mm) - average over buccal, palatal, distal and mesial measurements.


  6. Clinical Attachment Level (CAL) [ Time Frame: 6 months, 1 and 3 years ]

    The CAL will be measured from the crown margin to the bottom of the periimplant pocket by means of an UNC 15 probe.

    Clinical attachment level (mm) - average over buccal, palatal, distal and mesial measurements


  7. Bone Crest Levels. Bone Levels (mm) - Average Over Mesial+Distal Measurements [ Time Frame: 1 and 3 years ]

    Periapical radiographs are used to measure changes in mesial and distal bone crest levels (of the implant) from baseline (final loading) to one (1) year and three (3) years, respectively.

    The parameter derives from the subtraction of mesial and distal bone level linear x-ray measurements. The distance between the alveolar bone at the level of the first radiographic bone contact with the implant surface, and the shoulder of the implant will be measured to the closest 0.1mm at the mesial and distal surfaces of all implants on digitized standardized periapical x-rays using an image analysis computer programme. Bone levels are averaged over mesial+distal measurements. Since bone levels were measured from the implant shoulder, an increase in bone level over time corresponds to bone loss.


  8. Dental Implant Success and Implant Loss [ Time Frame: 3 years ]
    The implant success will be defined according to Buser et al 1990. Overall evaluation of implant success.

  9. Adverse Events [ Time Frame: up to 3 years ]
    All subjects are monitored continuously for adverse event.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects must have voluntarily signed the informed consent form before any study related action
  • Males and females must be at least 18 years of age and not more than 80 years old.
  • Partially edentulous in posterior (position 3-7) maxilla or mandible with implants planned for single crowns in an area with a healed extraction socket.
  • Adequate bone quality and quantity at the implant site to permit the insertion of a Straumann Soft Tissue Level implant of 4.1mm diameter without augmentation (at least 1mm bone buccally and lingually/palatal)

Exclusion Criteria:

  • Oral surgery contraindicated according to the judgement of the investigator (should be explained in the CRF)
  • Local inflammation, including untreated periodontitis
  • Patients with inadequate oral hygiene or unmotivated for adequate home care. Full mouth plaque index > 25% at time of surgery
  • Presence of conditions requiring chronic routine prophylactic use of antibiotics (e.g., history of rheumatic heart disease, bacterial endocarditis, cardiac valvular anomalies, prosthetic joint replacements)
  • Major systemic diseases
  • Medical conditions requiring prolonged use of steroids
  • Current pregnancy or breastfeeding women
  • Physical handicaps that would interfere with the ability to perform adequate oral hygiene
  • Use of any investigational drug or device within the 90 day period immediately prior to implant surgery on study day 0
  • Alcoholism or chronically drug abuse
  • Smokers; more than 10 cigarettes per day
  • Immuno-compromised patients
  • Conditions or circumstances, in the opinion of the investigator, which would prevent completion of study participation or interfere with analysis of study results, such as history of non-compliance, or unreliability.

Secondary Exclusion Criteria:

  • GBR procedures at or adjacent to the planned study site
  • Lack of primary stability of the dental implant at site of interest (e.g., rotational movement of the implant at a minimum of 15 Ncm torque at connection of the healing abutment, or tactile mobility)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02159183


Locations
Layout table for location information
Switzerland
University of Bern
Bern, Switzerland, 3010
University of Geneva
Geneva, Switzerland, 1211
Private Practice
Langenthal, Switzerland, 4900
Ardentis Clinique Dentaire
Lausanne, Switzerland, 1300
Sponsors and Collaborators
Institut Straumann AG
Investigators
Layout table for investigator information
Principal Investigator: Anton Sculean, Prof. Dr. Universität Bern, Klinik für Parodontologie

Layout table for additonal information
Responsible Party: Institut Straumann AG
ClinicalTrials.gov Identifier: NCT02159183     History of Changes
Other Study ID Numbers: CR 01/11
First Posted: June 9, 2014    Key Record Dates
Results First Posted: March 7, 2019
Last Update Posted: April 2, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Tooth Loss
Periodontal Diseases
Mouth Diseases
Stomatognathic Diseases
Tooth Diseases